Heart failure affects more than 64 million people worldwide (1%–3% in the general adult population) and its prevalence is ...
In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...
By early detection of fluid in the lungs, a device allows early therapy adjustments to reduce all-cause mortality in patients ...
In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...
Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI (TM) algorithm for cardiac amyloidosis (CA) -- the first and only cleared ...
A new systematic review and meta-analysis appearing in the Journal of Sport and Health Science suggests that combining strength and aerobic exercise may offer greater improvements ...
A research team from Cincinnati's Christ Hospital found that AI improved care and reduced hospitalizations for heart failure ...
NEW ORLEANS -- For people with heart failure with preserved ejection fraction (HFpEF), monitoring for early fluid ...
"ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose" was originally created and published by Pharmaceutical ...
AB-1002 is an investigational one-time gene therapy administered directly to the heart to promote production of a modified version (I-1c) of the naturally occurring protein inhibitor-1, designed to ...
Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary ...
HRS-1893 (also known as BHB-1893) is a selective, small-molecule, cardiac myosin inhibitor engineered to improve heart performance in patients with HCM. By modulating cardiac contractility, HRS-1893 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results